A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Public ClinicalTrials.gov record NCT06232707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Study identification
- NCT ID
- NCT06232707
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Alnuctamab Drug
- Pomalidomide Drug
- Daratumumab Drug
- Elotuzumab Drug
- Carfilzomib Drug
- Dexamethasone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2, 2024
- Primary completion
- Nov 15, 2025
- Completion
- Sep 20, 2030
- Last update posted
- May 30, 2024
2024 – 2030
United States locations
- U.S. sites
- 22
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0151 | Birmingham | Alabama | 35294 | — |
| Local Institution - 0088 | Los Angeles | California | 90095 | — |
| Local Institution - 0358 | Stanford | California | 94305 | — |
| Local Institution - 0355 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0434 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0433 | Wichita | Kansas | 67214 | — |
| Local Institution - 0439 | Saint Matthews | Kentucky | 40207 | — |
| Local Institution - 0323 | New Orleans | Louisiana | 70112 | — |
| Local Institution - 0324 | Baltimore | Maryland | 21218 | — |
| Local Institution - 0441 | Bethesda | Maryland | 20889 | — |
| Local Institution - 0435 | Billings | Montana | 59102 | — |
| Local Institution - 0157 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0359 | Summit | New Jersey | 07901 | — |
| Local Institution - 0430 | Lake Success | New York | 11042 | — |
| Local Institution - 0396 | New York | New York | 10065 | — |
| Local Institution - 0306 | Cincinnati | Ohio | 45220 | — |
| Local Institution - 0199 | Cleveland | Ohio | 44109 | — |
| Local Institution - 0437 | Pittsburgh | Pennsylvania | 15224 | — |
| Local Institution - 0352 | Providence | Rhode Island | 02903 | — |
| Local Institution - 0420 | Watertown | South Dakota | 57201 | — |
| Local Institution - 0168 | Dallas | Texas | 75390-88520 | — |
| Local Institution - 0405 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 148 non-U.S. sites.
Recently updated Multiple Myeloma trials
Other public records listing Multiple Myeloma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05201781: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Recruiting
- NCT07783607: MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Not yet recruiting
- NCT06152575: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting
- NCT07776964: Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) Not yet recruiting
- NCT07285239: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Recruiting
- NCT05976555: Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06232707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2024 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06232707 live on ClinicalTrials.gov.